Extract
It is well established that several of the interstitial lung diseases (ILDs) are driven by autoimmunity, such as rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. These are therefore considered to be autoimmune diseases and frequently treated with immunosuppressive drugs. Idiopathic pulmonary fibrosis (IPF) is not viewed as an autoimmune disorder, but nevertheless, autoantibodies routinely studied in clinical practice are found in IPF and other types of idiopathic interstitial pneumonias. Serological autoreactivities, such as anti-cyclic citrullinated peptide antibody (anti-CCP), antinuclear antibody, rheumatoid factor (RF) and anti-neutrophil cytoplasmic antibody, have been reported in IPF [1] similar to patients with a connective tissue disease.
Abstract
Localised autoimmune responses in the lungs might contribute to disease progression in IPF https://bit.ly/44c2D73
Footnotes
Conflict of interest: M. Mukherjee reports grants from Canadian Institutes of Health Research, Canadian Asthma Allergy Immunology Foundation, COVID Immunity Task Force, Methapharm Specialty Pharmaceuticals and Sanofi Aventis, and personal fees from AstraZeneca, GlaxoSmithKline and Novartis, outside the submitted work; and in addition, has a patent “Treatment strategy for non responders to 100 mg subcutaneous mepolizumab” issued. M. Kolb discloses relationships and activities with entities in the past 36 months, including research funding from Boehringer Ingelheim, United Therapeutics and Structure Therapeutics, and consulting fees from multiple entities including Boehringer Ingelheim, Roche, Horizon, Cipla, Abbvie, Bellerophon, Algernon, CSL Behring, United Therapeutics, LabCorp, Structure Therapeutics and CSL Behring; he has also received payment or honoraria for lectures, presentations, and educational events from Roche, Novartis and Boehringer Ingelheim, payment for expert testimony from Roche, and participated on advisory boards for United Therapeutics, LabCorp and Horizon; the author holds a leadership role as former chief editor for the ERJ, for which an allowance is received.
- Received April 17, 2023.
- Accepted April 21, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org